Dupilumab Reduced Oral Corticosteroid Use in Patients with OCS-Dependent Severe Asthma Consistently Across Baseline Disease Characteristics in the Phase 3 LIBERTY ASTHMA VENTURE Study

被引：0
|
作者：
Castro, M. [1 ]
Hanania, N. A. [2 ]
Daizadeh, N. [3 ]
Ortiz, B. [4 ]
Pandit-Abid, N. [5 ]
Deniz, Y. [4 ]
Rowe, P. [5 ]
机构：
[1] Univ Kansas, Sch Med, Kansas City, KS USA
[2] Baylor Coll Med, Houston, TX 77030 USA
[3] Sanofi, Cambridge, MA USA
[4] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[5] Sanofi, Bridgewater, NJ USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2020年 / 201卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3030
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Dupilumab Reduced Oral Corticosteroid (OCS) Use in Patients with OCS-Dependent, Severe Asthma Consistently Across Baseline Demographic Characteristics in the Phase 3 LIBERTY ASTHMA VENTURE Study
    Maspero, J. F.
    Ford, L. B.
    Daizadeh, N.
    Pandit-Abid, N.
    Ortiz, B.
    Rowe, P.
    Deniz, Y.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [2] Efficacy of dupilumab in patients with oral corticosteroid (OCS)-dependent, severe asthma with and without an allergic phenotype: phase 3 LIBERTY ASTHMA VENTURE
    Brusselle, Guy
    Papi, Alberto
    Chipps, Bradley E.
    Msihid, Jerome
    Jacob-Nara, Juby A.
    Deniz, Yamo
    Rowe, Paul
    Gall, Rebecca
    Ortiz, Benjamin
    Djandji, Michel
    Radwan, Amr
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [3] DUPILUMAB REDUCED ORAL CORTICOSTEROID USE AND IMPROVED CLINICAL OUTCOMES REGARDLESS OF BASELINE OCS DOSE IN PATIENTS WITH UNCONTROLLED, SEVERE ASTHMA IN THE LIBERTY ASTHMA VENTURE STUDY
    Ribas, Cristian Domingo
    Maspero, Jorge
    Castro, Mario
    Hanania, Nicola
    Ford, Linda
    Halpin, David
    Jackson, David
    Daizadeh, Nadia
    Djandji, Michel
    Mitchell, Colin
    Crikelair, Nora
    Jacob-Nara, Juby
    Deniz, Yamo
    Rowe, Paul
    Ortiz, Benjamin
    CHEST, 2021, 160 (04) : 1893A - 1897A
  • [4] Persistent Reductions in OCS Use in Patients with Severe, OCS-Dependent Asthma Treated with Dupilumab: LIBERTY ASTHMA TRAVERSE Study
    Gurnell, M.
    Ribas, C. Domingo
    Rabe, K. F.
    Menzies-Gow, A.
    Price, D.
    Brusselle, G.
    Wechsler, M. E.
    Xia, C.
    Djandji, M.
    Gall, R.
    Jacob-Nara, J. A.
    Rowe, P. J.
    Deniz, Y.
    Siddiqui, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [5] Persistent reductions in OCS use in patients with severe, OCS-dependent asthma treated with dupilumab: LIBERTY -ASTHMA TRAVERSE study
    Gurnell, M.
    Domingo, C.
    Rabe, K. F.
    Menzies-Gow, A.
    Price, D.
    Brusselle, G.
    Wechsler, M. E.
    Xia, C.
    Djandji, M.
    Gall, R.
    Jacob-Nara, J. A.
    Rowe, P. J.
    Deniz, Y.
    Siddiqui, S.
    ALLERGOLOGIE, 2022, 45 (08) : 610 - 611
  • [6] DUPILUMAB REDUCED OCS USE IN ASTHMA PATIENTS ACROSS BASELINE CHARACTERISTICS
    Castro, M.
    Hanania, N.
    Daizadeh, N.
    Ortiz, B.
    Pandit-Abid, N.
    Deniz, Y.
    Rowe, P.
    RESPIROLOGY, 2021, 26 : 40 - 40
  • [7] Dupilumab sustains improvements in clinical efficacy and reductions in OCS use in patients with severe, OCS-dependent asthma: LIBERTY ASTHMA TRAVERSE study
    Park, Hye Yun
    Gurnell, Mark
    Domingo, Christian
    Rabe, Klaus F.
    Menzies-Gow, Andrew
    Price, David
    Brusselle, Guy
    Wechsler, Michael E.
    Xia, Changming
    Pandit-Abid, Nami
    Gall, Rebecca
    Jacob-Nara, Juby A.
    Rowe, Paul J.
    Deniz, Yamo
    Siddiqui, Shahid
    RESPIROLOGY, 2023, 28 : 20 - 22
  • [8] Dupilumab Improved Morning and Evening Daily Asthma Symptoms in Patients with Oral-Corticosteroid-Dependent Severe Asthma in the Phase 3 LIBERTY ASTHMA VENTURE Study
    Sher, L.
    Rabe, K. F.
    Wolfe, R. N.
    Quirce, S.
    Rice, M. S.
    Rowe, P.
    Lu, Y.
    Kamat, S.
    Amin, N.
    Graham, N. M. H.
    Teper, A.
    Khan, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [9] Association Of Baseline Lung Function And Likelihood Of Oral Corticosteroid Reduction In Patients With OCS-Dependent Severe Asthma
    Domingo, Christian
    Hanania, Nicola
    Canonica, Giorgio
    Halpin, David
    Lugogo, Njira
    Rhee, Chin Kook
    Altincatal, Arman
    Pandit-Abid, Nami
    Nash, Scott
    Deniz, Yamo
    Rowe, Paul
    Sacks, Harry
    Jacob-Nara, Juby
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB102 - AB102
  • [10] Dupilumab reduces OCS use and improves lung function in patients with severe OCS-dependent asthma
    Gurnell, M.
    Domingo, C.
    Rabe, K. F.
    Menzies-Gow, A.
    Price, D.
    Brusselle, G.
    Wechsler, M. E.
    Xia, C.
    Pandit-Abid, N.
    Gall, R.
    Jacob-Nara, J. A.
    Rowe, P. J.
    Deniz, Y.
    Siddiqui, S.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
12345